Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

INTRODUCTION: Antiviral drugs have shown limited effectiveness in treating patients with coronavirus disease 2019 (COVID-19). We aimed to assess the effects of a favipiravir and hydroxychloroquine combination on treating moderate-to-severe COVID-19 patients. METHODS: An investigator-initiated, multi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Infect Dis Ther
Glavni autori: Bosaeed, Mohammad, Mahmoud, Ebrahim, Alharbi, Ahmad, Altayib, Hadeel, Albayat, Hawra, Alharbi, Faisal, Ghalilah, Khalid, Al Arfaj, Abdulmajid, AlJishi, Jumana, Alarfaj, Abdullatif, Alqahtani, Hajar, Almutairi, Badriah M., Almaghaslah, Manar, Alyahya, Nawaf M., Bawazir, Abdullah, AlEisa, Saud, Alsaedy, Abdulrahman, Bouchama, Abderrezak, Alharbi, Malak, AlShamrani, Majid, Al Johani, Sameera, Aljeraisy, Majed, Alzahrani, Mohammed, Althaqafi, Abdulhakeem O., Almarhabi, Hassan, Alotaibi, Athari, Alqahtani, Nasser, Arabi, Yaseen M., Aldibasi, Omar S., Alaskar, Ahmad
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2021
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8316887/
https://ncbi.nlm.nih.gov/pubmed/34319552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-021-00496-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items